Ann: Half Yearly Report and Accounts, page-4

When you discover something with the earnings potential like this,

lets say a profit $?? from test (out of 350 cost) ??? Theres going to be a margin in there somewhere.
They dont just supply the test at cost basis.

Anyway, thats a volume target market in AUS of 900k pa who get mams,(and 27m in the USA) - now who that is health conscious enough to sit through a mam, wouldnt also give a blood sample if it was more sensitive ? Add all the others in a growth market would would just do it at the behest of their GP check up every now and then ?

Also consider the possible increase risk that some may now potentially face, video link below mentions impairment of P53 cancer defender genomes (skin and renal, and a few others) and BRCA ( breast, ovarian and a few other female reproductive) from your not so safe, nor fully tested genetic product. (that skipped cancer and genotoxicity studies prior to mass release).